FDA asks for public comment on generative AI medical devices

By Atlas Watchline Staff · Regulatory · August 18, 2026

The FDA has issued a discussion paper on generative AI-enabled medical devices and is seeking public feedback by Oct. 19, 2026.

The FDA has issued a discussion paper on generative AI-enabled medical devices and is seeking public feedback by Oct. 19, 2026.

What happened

The U.S. Food and Drug Administration said on Aug. 18, 2026, that it issued a discussion paper on considerations for regulating generative artificial intelligence-enabled medical devices. The agency is asking device manufacturers, clinicians, consumers, researchers, the public and other interested parties to comment through docket FDA-2026-N-7874 on Regulations.gov by Oct. 19, 2026.

Why it matters

The FDA said generative AI-enabled devices may bring new capabilities to patient care, but they may also create risks that differ from those tied to traditional software and other AI-enabled medical devices. The paper is intended to help shape how the agency evaluates risk, reviews products before they reach patients and monitors them after they are on the market.

Context and background

According to the FDA, the discussion paper outlines a possible two-axis framework for risk assessment. It also describes a competency-based approach to premarket review that would use non-clinical benchmarking and clinical confirmation to judge whether a device performs as intended.

The paper also discusses risk-proportionate postmarket monitoring and asks questions about foundation models and agentic AI systems. The agency said the effort supports its broader work on AI and digital health regulatory frameworks and its public health pillar on innovation and global leadership.

What officials said

Acting FDA Commissioner Kyle Diamantas said artificial intelligence is transforming medicine and that the United States must help shape how the technology is developed and used safely and responsibly.

Michelle Tarver, director of the FDA Center for Devices and Radiological Health, said patients and clinicians deserve a regulatory approach that keeps pace with digital health innovation. She said the agency is launching a transparent process to develop an approach that safeguards patients and consumers while advancing innovation.

Rick Abramson, director of the FDA’s Digital Health Center of Excellence, said generative AI-enabled medical devices are poised to reshape health technology and that the discussion paper is intended to advance regulatory science and public-health protections.

What happens next

The FDA said it will review public input submitted under docket FDA-2026-N-7874 on Regulations.gov through Oct. 19, 2026. The agency said the discussion paper will help inform its regulatory approach to generative AI-enabled medical devices.

Sources

• FDA press release: FDA seeks public feedback to inform regulatory approach for generative AI-enabled medical devices

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.